New York, NY -- (SBWIRE) -- 03/01/2016 -- Abeona Therapeutics, Inc., a biopharmaceutical company focused on developing and delivering products for severe and life-threatening rare diseases, today announced the FDA cleared the Company's Investigational New Drug Application for ABO-102 (AAV- SGSH), a single treatment strategy for Mucopolysaccharidosis Type IIIA (MPS IIIA). The ABO-102 IND application is now active and enables Nationwide Children's Hospital (Columbus, OH) to initiate a Phase 1/2 clinical study designed to assess the safety, tolerability and potential efficacy of ABO-102 in children with MPS IIII A.
Read the full press release at http://www.sbwire.com/press-releases/abeona-therapeutics-announces-fda-allowance-of-investigational-new-drug-for-systemic-aav-phase-12-clinical-study-in-patients-with-sanfilippo-syndrome-type-a-mps-iiia-668998.htm